Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • Drusas@kbin.social
    link
    fedilink
    arrow-up
    15
    ·
    1 year ago

    As a high-risk individual, this fucking sucks. Capitalist vultures trying to bankrupt me everywhere I turn.

    • Franzia
      link
      fedilink
      arrow-up
      3
      ·
      1 year ago

      Oh dear I read this wrong at first, thinking you were flexing that you take risks. I’m thinking “well my life is boring and this sucks for me too?” 🤣

  • malloc@lemmy.world
    link
    fedilink
    English
    arrow-up
    9
    ·
    1 year ago

    Health insurance companies probably finding some obscure study to deny claims for Paxlovid. Or just follow UHC claim practices. Deny all claims initially. Slow roll it.

    Patient either gives up or pays out of pocket.

  • Stuka@lemmy.ml
    link
    fedilink
    arrow-up
    4
    ·
    1 year ago

    Honestly 1400 for a 5 day course of this is more reasonable than I expected. It’s still unreasonable, but I just figured it’s be way higher.